SCHEMBL6170316

SCHEMBL6170316

Cc1onc(-c2ccc(F)c(F)c2)c1-c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 18/20 0.74
▸ PTGS1 P23219 8/20 0.68
▸ MT-CO2 P00403 3/20 0.68
▸ CA12 O43570 1/20 0.68
▸ CA1 P00915 1/20 0.68
▸ CA2 P00918 1/20 0.68
▸ LMNA P02545 1/20 0.68
▸ CA3 P07451 1/20 0.68
▸ ADRB2 P07550 1/20 0.68
▸ ADRB1 P08588 1/20 0.68
▸ CYP3A4 P08684 1/20 0.68
▸ ADORA3 P0DMS8 1/20 0.68
▸ CHRM1 P11229 1/20 0.68
▸ ADRA2B P18089 1/20 0.68
▸ CA4 P22748 1/20 0.68
▸ CA6 P23280 1/20 0.68
▸ SLC6A2 P23975 1/20 0.68
▸ PDE4A P27815 1/20 0.68
▸ ADORA1 P30542 1/20 0.68
▸ CA5A P35218 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891025 0.91 PTGS2 (0.73) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6171538 0.88 PTGS2 (0.74) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6728511 0.87 PTGS2 (0.56) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL27527364 0.87 PTGS2 (0.67) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL4888565 0.87 PTGS2 (0.67) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6721410 0.86 PTGS2 (0.55) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6169904 0.86 PTGS2 (0.81) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL6168064 0.85 PTGS2 (0.68) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL4800858 0.85 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1
SCHEMBL14267686 0.85 PTGS2 (1.00) PTGS2PTGS1MT-CO2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 — — EP claimed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 — — EP claimed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 — — EP claimed
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 — — EP disclosed
CN-1442139-A Medicinal composition for treating inflammation SEARLE & CO (US) 2003-09-17 — — CN disclosed
CN-1107058-C Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 2003-04-30 — — CN disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 — — EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 — — EP disclosed
CN-1181075-A Substituted isoxazoles for the treatment of disorders SEARLE & CO (US) 1998-05-06 — — CN disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 — — EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 — — WO disclosed
Send feedback